Who Owns Coherus Oncology Stock?
NASDAQ: CHRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 37.22%
- Held by insiders
- 19.12%
- Institutional holders
- 193
- Institutions 37.2%
- Insiders 19.1%
- Public and other 43.7%
Who owns Coherus Oncology stock?
Institutional investors own about 37.2% of Coherus Oncology's shares, spread across 193 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 19.12% of CHRS.
The largest institutional holders are Timothy G. Youngquist 2020 Irrevocable Trust (16.89%), Blackrock Inc. (15.54%) and Vanguard Capital Management LLC (7.70%). Together, the top 10 institutions control 64.5% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their CHRS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CHRS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 26.10M | 16.89% | 0.0% |
| Blackrock Inc. | 24.01M | 15.54% | +15.8% |
| Vanguard Capital Management LLC | 11.90M | 7.70% | +9.1% |
| Geode Capital Management, LLC | 7.37M | 4.77% | +18.1% |
| Samsara BioCapital, LLC | 6.86M | 4.44% | 0.0% |
| Kohlberg Kravis Roberts & Co. L.P. | 6.07M | 3.93% | 0.0% |
| State Street Corporation | 4.76M | 3.08% | +2.4% |
| Two Sigma Investments, LP | 4.52M | 2.92% | -1.9% |
| CM Management, LLC | 4.20M | 2.72% | 0.0% |
| C WorldWide Group Holding A/S | 3.86M | 2.50% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CHRS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7.91M | 5.12% |
| iShares Trust-iShares Russell 2000 ETF | 6.54M | 4.23% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.73M | 2.41% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.65M | 1.72% |
| BlackRock Funds-BlackRock Advantage Small Cap Core Fund | 1.86M | 1.20% |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 1.80M | 1.17% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 1.53M | 0.99% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 1.49M | 0.97% |
| iShares Trust-iShares Russell 2000 Value ETF | 1.49M | 0.96% |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 1.41M | 0.91% |
Frequently asked questions
Who is the largest shareholder of Coherus Oncology?
Timothy G. Youngquist 2020 Irrevocable Trust is the largest institutional shareholder of CHRS, owning 16.89% of shares outstanding (26.10M shares) as of its latest 13F filing.
What percentage of Coherus Oncology is owned by institutions?
Institutions own about 37.2% of CHRS shares and 46.0% of the public float.
How much of Coherus Oncology do insiders own?
Insiders, such as officers and directors, own about 19.12% of CHRS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.